\-\ Texto\\:\\ \ \(0\)\
\-\ right\\ knee\\ findings\\:\ \(0\)\
\-\ minimal\\ warmth\\ noted\\.\\ \ \(0\)\
\-\ no\\ erythema\\.\ \(1\)\
\-\ no\\ subcutaneous\\ nodules\\.\\ \ \(0\)\
\-\ minimally\\ tender\\ to\\ palpation\\ along\\ joint\\ line\\.\\ \ \(0\)\
\-\ full\\ range\\ with\\ both\\ active\\ and\\ passive\\ motion\\.\\ \\ \ \(0\)\
\-\ negative\\ anterior\\/posterior\\ drawer\\ sign\\.\ \(0\)\
\-\ the\\ issue\\ of\\ ongoing\\ urate\\ deposition\\ should\\ be\\ addressed\\ with\\ uricosuric\\ medication\\.\\ \\ probenecid\\ \\(benemid\\)\\ is\\ the\\ most\\ frequently\\ used\\ medication\\.\\ \\ probenecid\\ works\\ at\\ the\\ level\\ of\\ the\\ proximal\\ tubule\\ by\\ blocking\\ reabsorption\\ of\\ filtered\\ uric\\ acid\\.\\ this\\ action\\ is\\ inhibited\\ by\\ low\\-dose\\ salicylates\\;\\ this\\ fact\\ accounts\\ for\\ a\\ significant\\ number\\ of\\ \\"treatment\\ failures\\.\\"\\ allopurinol\\ \\(zyloprim\\)\\ can\\ also\\ be\\ used\\ and\\ is\\ currently\\ the\\ only\\ readily\\ available\\ inhibitor\\ of\\ uric\\ acid\\ synthesis\\.\ \(0\)\
\-\ tophi\\ should\\ not\\ be\\ surgically\\ removed\\ unless\\ they\\ are\\ in\\ a\\ critical\\ location\\ or\\ drain\\ chronically\\.\ \(0\)\
\-\ there\\ is\\ no\\ evidence\\ of\\ bone\\ marrow\\ abnormality\\.\\ \\ a\\ small\\ joint\ \(0\)\
\-\ effusion\\ is\\ present\\.\\ \\ a\\ large\\ nodular\\ mass\\ is\\ seen\\ adjacent\\ to\\ the\\ lateral\\ superior\\ patella\\ with\\ isointense\\ signal\\ on\\ t1\\ and\\ heterogeneous\\ signal\\ on\\ t2\\ measuring\\ approximately\\ 5\\.2\\ x\\ 1\\.8\\ x\\ 6\\ cm\\.\\ smaller\\ similar\\ masses\\ are\\ present\\ at\\ the\\ femoropopliteal\\ insertion\\ site\\,\\ within\\ the\\ femoral\\ notch\\ and\\ at\\ the\\ base\\ of\\ the\\ hoffa\\'s\\ fat\\ pad\\ just\\ anterior\\ to\\ the\\ anteromedial\\ tibia\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ the\\ pcl\\ appears\\ thickened\\ but\\ intact\\.\\ \\ the\\ acl\\,\\ menisci\\,\\ and\\ collateral\ \(0\)\
\-\ ligament\\ complexes\\ are\\ unremarkable\\.\\ \\ full\\ thickness\\ fissuring\\ is\\ present\\ in\\ the\\ medial\\ trochlea\\ cartilage\\.\ \(0\)\
\-\ tophaceous\\ gout\ \(5\)\
\-\ \\>\\>\\ gout\ \(0\)\
\-\ \\>\\>\\ pigmented\\ villonodular\\ synovitis\ \(0\)\
\-\ \\>\\>\\ pseudogout\ \(0\)\
\-\ \\>\\>\\ tumor\ \(0\)\
\-\ \\>\\>\\ uric\\ acid\\ nephropathy\ \(0\)\
\-\ \\>\\>\\ rheumatoid\\ arthritis\ \(0\)\
\-\ \\>\\>\\ sarcoidosis\ \(0\)\
\-\ \\>\\>\\ amyloidosis\ \(0\)\
\-\ 40\\ year\\ old\\ male\\ with\\ history\\ of\\ gout\\ presents\\ with\\ chronic\\ knee\\ pain\\ for\\ 5\\ months\\.\ \(1\)\
\-\ mri\\ is\\ not\\ used\\ routinely\\ in\\ the\\ evaluation\\ of\\ gout\\.\\ however\\,\\ when\\ gouty\\ tophi\\ present\\ as\\ soft\\-tissue\\ masses\\ in\\ the\\ absence\\ of\\ articular\\ disease\\,\\ the\\ tophi\\ may\\ be\\ confused\\ with\\ a\\ neoplastic\\ process\\.\\ in\\ this\\ instance\\,\\ mri\\ evaluation\\ is\\ necessary\\.\\ tophaceous\\ deposition\\ should\\ be\\ considered\\ in\\ the\\ differential\\ diagnosis\\ when\\ a\\ mass\\ displays\\ heterogeneous\\ low\\ to\\ intermediate\\ signal\\ intensity\\ on\\ t1\\ and\\ t2\\ weighting\\ and\\ a\\ variable\\ enhancement\\ pattern\\,\\ especially\\ if\\ multiple\\ foci\\ exist\\ around\\ the\\ knee\\ joint\\ such\\ as\\ in\\ this\\ individual\\.\\ remarkably\\,\\ the\\ adjacent\\ bone\\ to\\ these\\ particular\\ tophi\\ did\\ not\\ show\\ typical\\ erosive\\ changes\\,\\ which\\ is\\ an\\ unexpected\\ finding\\ in\\ a\\ patient\\ with\\ a\\ chronic\\ history\\ of\\ gout\\ and\\ knee\\ pain\\.\\ as\\ such\\,\\ needle\\ biopsy\\ was\\ necessary\\ to\\ rule\\ out\\ a\\ neoplastic\\ and\\ chronic\\ infectious\\ etiology\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ tophi\\:\\ 0\\.29737139337996443\ \(0\)\
\-\ gout\\:\\ 0\\.2606920522123405\ \(0\)\
\-\ the\\:\\ 0\\.206231289152463\ \(0\)\
\-\ uric\\:\\ 0\\.19705969507713106\ \(0\)\
\-\ acid\\:\\ 0\\.16099805233024822\ \(0\)\
\-\ probenecid\\:\\ 0\\.15794116160163432\ \(0\)\
\-\ knee\\:\\ 0\\.14816767107957968\ \(0\)\
\-\ is\\:\\ 0\\.1415227659398372\ \(0\)\
\-\ tophaceous\\:\\ 0\\.1361268133650101\ \(0\)\
\-\ used\\:\\ 0\\.11606318118430581\ \(0\)\
\-\ of\\:\\ 0\\.11124396925697874\ \(0\)\
\-\ present\\:\\ 0\\.10606993044768563\ \(0\)\
\-\ be\\:\\ 0\\.10481779095124455\ \(0\)\
\-\ deposition\\:\\ 0\\.10427682088493619\ \(0\)\
\-\ in\\:\\ 0\\.10284578492176306\ \(0\)\
\-\ joint\\:\\ 0\\.10215875932684766\ \(0\)\
\-\ should\\:\\ 0\\.10115899757169022\ \(0\)\
\-\ and\\:\\ 0\\.09610699025220278\ \(0\)\
\-\ medication\\:\\ 0\\.09552820409126501\ \(0\)\
\-\ neoplastic\\:\\ 0\\.09552820409126501\ \(0\)\
\-\ chronic\\:\\ 0\\.09202313491332295\ \(0\)\
\-\ signal\\:\\ 0\\.08788377805368233\ \(0\)\
\-\ necessary\\:\\ 0\\.08646652325882617\ \(0\)\
\-\ uricosuric\\:\\ 0\\.0826438186988376\ \(0\)\
\-\ benemid\\:\\ 0\\.0826438186988376\ \(0\)\
\-\ filtered\\:\\ 0\\.0826438186988376\ \(0\)\
\-\ zyloprim\\:\\ 0\\.0826438186988376\ \(0\)\
\-\ fissuring\\:\\ 0\\.0826438186988376\ \(0\)\
\-\ full\\:\\ 0\\.08079246938912277\ \(0\)\
\-\ tubule\\:\\ 0\\.07897058080081716\ \(0\)\
\-\ inhibited\\:\\ 0\\.07897058080081716\ \(0\)\
\-\ salicylates\\:\\ 0\\.07897058080081716\ \(0\)\
\-\ femoropopliteal\\:\\ 0\\.07897058080081716\ \(0\)\
\-\ weighting\\:\\ 0\\.07897058080081716\ \(0\)\
\-\ to\\:\\ 0\\.07751587165104787\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.07480626899058875\ \(0\)\
\-\ urate\\:\\ 0\\.07434284834499111\ \(0\)\
\-\ remarkably\\:\\ 0\\.07434284834499111\ \(0\)\
\-\ reabsorption\\:\\ 0\\.07269113913833111\ \(0\)\
\-\ failures\\:\\ 0\\.07269113913833111\ \(0\)\
\-\ synthesis\\:\\ 0\\.07269113913833111\ \(0\)\
\-\ blocking\\:\\ 0\\.07129463890236987\ \(0\)\
\-\ trochlea\\:\\ 0\\.07129463890236987\ \(0\)\
\-\ this\\:\\ 0\\.07102948994862597\ \(0\)\
\-\ with\\:\\ 0\\.0708339147740648\ \(0\)\
\-\ masses\\:\\ 0\\.07036231353868168\ \(0\)\
\-\ allopurinol\\:\\ 0\\.07008493537386552\ \(0\)\
\-\ hoffa\\:\\ 0\\.06901790124031065\ \(0\)\
\-\ complexes\\:\\ 0\\.06901790124031065\ \(0\)\
\-\ pseudogout\\:\\ 0\\.06901790124031065\ \(0\)\
\-\ instance\\:\\ 0\\.06901790124031065\ \(0\)\
\-\ addressed\\:\\ 0\\.06719996132673108\ \(0\)\
\-\ works\\:\\ 0\\.06719996132673108\ \(0\)\
\-\ chronically\\:\\ 0\\.06719996132673108\ \(0\)\
\-\ adjacent\\:\\ 0\\.06699492810855175\ \(0\)\
\-\ such\\:\\ 0\\.06648340162062805\ \(0\)\
\-\ routinely\\:\\ 0\\.06641169747584506\ \(0\)\
\-\ gouty\\:\\ 0\\.06501519723988382\ \(0\)\
\-\ t1\\:\\ 0\\.06439681522121923\ \(0\)\
\-\ nephropathy\\:\\ 0\\.0643901687844846\ \(0\)\
\-\ inhibitor\\:\\ 0\\.06325627590211268\ \(0\)\
\-\ evaluation\\:\\ 0\\.06303186484558058\ \(0\)\
\-\ when\\:\\ 0\\.06243258631071\ \(0\)\
\-\ as\\:\\ 0\\.06228224278403024\ \(0\)\
\-\ menisci\\:\\ 0\\.06224864735418524\ \(0\)\
\-\ villonodular\\:\\ 0\\.06224864735418524\ \(0\)\
\-\ issue\\:\\ 0\\.061783965020019004\ \(0\)\
\-\ action\\:\\ 0\\.061783965020019004\ \(0\)\
\-\ displays\\:\\ 0\\.061341959341863365\ \(0\)\
\-\ exist\\:\\ 0\\.061341959341863365\ \(0\)\
\-\ not\\:\\ 0\\.06120332532415235\ \(0\)\
\-\ readily\\:\\ 0\\.06092051966424502\ \(0\)\
\-\ drawer\\:\\ 0\\.06013225581335901\ \(0\)\
\-\ anteromedial\\:\\ 0\\.06013225581335901\ \(0\)\
\-\ unexpected\\:\\ 0\\.06013225581335901\ \(0\)\
\-\ t2\\:\\ 0\\.05946316147804693\ \(0\)\
\-\ pcl\\:\\ 0\\.059407123363224304\ \(0\)\
\-\ low\\:\\ 0\\.05930583511741969\ \(0\)\
\-\ are\\:\\ 0\\.05882795800456481\ \(0\)\
\-\ warmth\\:\\ 0\\.05873575557739777\ \(0\)\
\-\ at\\:\\ 0\\.05855791219692549\ \(0\)\
\-\ notch\\:\\ 0\\.058110727121998544\ \(0\)\
\-\ pigmented\\:\\ 0\\.058110727121998544\ \(0\)\
\-\ individual\\:\\ 0\\.058110727121998544\ \(0\)\
\-\ anterior\\:\\ 0\\.05770756417687838\ \(0\)\
\-\ ongoing\\:\\ 0\\.05752605204889341\ \(0\)\
\-\ accounts\\:\\ 0\\.05752605204889341\ \(0\)\
\-\ critical\\:\\ 0\\.056976834239626635\ \(0\)\
\-\ amyloidosis\\:\\ 0\\.056976834239626635\ \(0\)\
\-\ bone\\:\\ 0\\.056393877214056524\ \(0\)\
\-\ synovitis\\:\\ 0\\.056210801858415066\ \(0\)\
\-\ pad\\:\\ 0\\.055733885465203845\ \(0\)\
\-\ passive\\:\\ 0\\.05528082509458922\ \(0\)\
\-\ acl\\:\\ 0\\.05528082509458922\ \(0\)\
\-\ erosive\\:\\ 0\\.05484934738896766\ \(0\)\
\-\ confused\\:\\ 0\\.05464107800175897\ \(0\)\
\-\ patella\\:\\ 0\\.05423837528913632\ \(0\)\
\-\ mri\\:\\ 0\\.053053444204222804\ \(0\)\
\-\ intermediate\\:\\ 0\\.0527857800173181\ \(0\)\
\-\ drain\\:\\ 0\\.051534231983259605\ \(0\)\
\-\ unless\\:\\ 0\\.05083160717040685\ \(0\)\
\-\ insertion\\:\\ 0\\.05069739257714058\ \(0\)\
\-\ particular\\:\\ 0\\.05043478522355125\ \(0\)\
\-\ no\\:\\ 0\\.050414954978460984\ \(0\)\
\-\ variable\\:\\ 0\\.05017957625285251\ \(0\)\
\-\ fact\\:\\ 0\\.04957133986777727\ \(0\)\
\-\ collateral\\:\\ 0\\.0494544438027178\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.0492250816950469\ \(0\)\
\-\ minimally\\:\\ 0\\.04900138343210317\ \(0\)\
\-\ cartilage\\:\\ 0\\.04900138343210317\ \(0\)\
\-\ surgically\\:\\ 0\\.04795893362665027\ \(0\)\
\-\ thickness\\:\\ 0\\.04795893362665027\ \(0\)\
\-\ needle\\:\\ 0\\.04795893362665027\ \(0\)\
\-\ number\\:\\ 0\\.04757337248838692\ \(0\)\
\-\ articular\\:\\ 0\\.047203553003686435\ \(0\)\
\-\ on\\:\\ 0\\.04682261544925786\ \(0\)\
\-\ erythema\\:\\ 0\\.0467615473255308\ \(0\)\
\-\ isointense\\:\\ 0\\.0467615473255308\ \(0\)\
\-\ smaller\\:\\ 0\\.046506338354832054\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.04555184379702644\ \(0\)\
\-\ ligament\\:\\ 0\\.04441795091465453\ \(0\)\
\-\ tibia\\:\\ 0\\.0441553435610652\ \(0\)\
\-\ removed\\:\\ 0\\.04390013459036646\ \(0\)\
\-\ by\\:\\ 0\\.04389065795342532\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.043775176480327097\ \(0\)\
\-\ thickened\\:\\ 0\\.043590912785425796\ \(0\)\
\-\ marrow\\:\\ 0\\.04294564003256085\ \(0\)\
\-\ frequently\\:\\ 0\\.04255772000368502\ \(0\)\
\-\ foci\\:\\ 0\\.0422379461236068\ \(0\)\
\-\ arthritis\\:\\ 0\\.04203086695112043\ \(0\)\
\-\ site\\:\\ 0\\.04167949196416422\ \(0\)\
\-\ etiology\\:\\ 0\\.0416303898420825\ \(0\)\
\-\ infectious\\:\\ 0\\.0415815524227531\ \(0\)\
\-\ just\\:\\ 0\\.04134123808403314\ \(0\)\
\-\ around\\:\\ 0\\.041246869320867074\ \(0\)\
\-\ absence\\:\\ 0\\.04120005102883105\ \(0\)\
\-\ nodular\\:\\ 0\\.04115347344887128\ \(0\)\
\-\ nodules\\:\\ 0\\.0410610306126017\ \(0\)\
\-\ rule\\:\\ 0\\.04101516054323201\ \(0\)\
\-\ especially\\:\\ 0\\.04087892760990034\ \(0\)\
\-\ line\\:\\ 0\\.040268935372635095\ \(0\)\
\-\ considered\\:\\ 0\\.040268935372635095\ \(0\)\
\-\ range\\:\\ 0\\.040101938582306644\ \(0\)\
\-\ motion\\:\\ 0\\.0400606659854264\ \(0\)\
\-\ measuring\\:\\ 0\\.039978680635422516\ \(0\)\
\-\ typical\\:\\ 0\\.03993796452488084\ \(0\)\
\-\ currently\\:\\ 0\\.03969743749362925\ \(0\)\
\-\ history\\:\\ 0\\.039487710824006234\ \(0\)\
\-\ mass\\:\\ 0\\.03947896841674757\ \(0\)\
\-\ minimal\\:\\ 0\\.039424663186654836\ \(0\)\
\-\ similar\\:\\ 0\\.039386357339536375\ \(0\)\
\-\ base\\:\\ 0\\.03931022815753618\ \(0\)\
\-\ process\\:\\ 0\\.038758780910742203\ \(0\)\
\-\ pattern\\:\\ 0\\.03858218039946126\ \(0\)\
\-\ femoral\\:\\ 0\\.038408956778766414\ \(0\)\
\-\ active\\:\\ 0\\.038374706003200906\ \(0\)\
\-\ effusion\\:\\ 0\\.038374706003200906\ \(0\)\
\-\ 40\\:\\ 0\\.03800625406614376\ \(0\)\
\-\ appears\\:\\ 0\\.03784360482570529\ \(0\)\
\-\ tender\\:\\ 0\\.037779354064574715\ \(0\)\
\-\ abnormality\\:\\ 0\\.03758929144290169\ \(0\)\
\-\ intact\\:\\ 0\\.03740313449529437\ \(0\)\
\-\ did\\:\\ 0\\.03707147511861362\ \(0\)\
\-\ pain\\:\\ 0\\.03698433267689974\ \(0\)\
\-\ they\\:\\ 0\\.03692464338986887\ \(0\)\
\-\ intensity\\:\\ 0\\.036694553070361555\ \(0\)\
\-\ biopsy\\:\\ 0\\.03622419269191916\ \(0\)\
\-\ location\\:\\ 0\\.0359847253747833\ \(0\)\
\-\ sign\\:\\ 0\\.03577705280033848\ \(0\)\
\-\ available\\:\\ 0\\.03506179642154709\ \(0\)\
\-\ palpation\\:\\ 0\\.03485083249241138\ \(0\)\
\-\ unremarkable\\:\\ 0\\.03464466967871434\ \(0\)\
\-\ along\\:\\ 0\\.03462204964362658\ \(0\)\
\-\ finding\\:\\ 0\\.0339684499855973\ \(0\)\
\-\ out\\:\\ 0\\.0339684499855973\ \(0\)\
\-\ medial\\:\\ 0\\.03363823322491929\ \(0\)\
\-\ superior\\:\\ 0\\.03359778976781228\ \(0\)\
\-\ differential\\:\\ 0\\.033577635545159475\ \(0\)\
\-\ approximately\\:\\ 0\\.032974106522801756\ \(0\)\
\-\ show\\:\\ 0\\.032806163764597454\ \(0\)\
\-\ proximal\\:\\ 0\\.03228526656310029\ \(0\)\
\-\ only\\:\\ 0\\.03228526656310029\ \(0\)\
\-\ fat\\:\\ 0\\.03214668918653466\ \(0\)\
\-\ negative\\:\\ 0\\.0319932821829487\ \(0\)\
\-\ for\\:\\ 0\\.03132620052021296\ \(0\)\
\-\ changes\\:\\ 0\\.03123181898494088\ \(0\)\
\-\ level\\:\\ 0\\.031216293155355\ \(0\)\
\-\ however\\:\\ 0\\.030587128968614367\ \(0\)\
\-\ months\\:\\ 0\\.030080575452885054\ \(0\)\
\-\ if\\:\\ 0\\.030026001074916008\ \(0\)\
\-\ significant\\:\\ 0\\.029837538898321962\ \(0\)\
\-\ enhancement\\:\\ 0\\.029744757933122746\ \(0\)\
\-\ cm\\:\\ 0\\.029679062798634692\ \(0\)\
\-\ evidence\\:\\ 0\\.02933231370788287\ \(0\)\
\-\ these\\:\\ 0\\.029182362929756678\ \(0\)\
\-\ both\\:\\ 0\\.02881799802869652\ \(0\)\
\-\ noted\\:\\ 0\\.027399416380940917\ \(0\)\
\-\ can\\:\\ 0\\.027118795558107117\ \(0\)\
\-\ tumor\\:\\ 0\\.027030411253681417\ \(0\)\
\-\ most\\:\\ 0\\.026894615915777735\ \(0\)\
\-\ diagnosis\\:\\ 0\\.02678932945570073\ \(0\)\
\-\ small\\:\\ 0\\.026657074269676014\ \(0\)\
\-\ may\\:\\ 0\\.02600582490061424\ \(0\)\
\-\ large\\:\\ 0\\.025893069829453615\ \(0\)\
\-\ lateral\\:\\ 0\\.025646484676013437\ \(0\)\
\-\ but\\:\\ 0\\.0255546805621572\ \(0\)\
\-\ findings\\:\\ 0\\.025504994956740593\ \(0\)\
\-\ multiple\\:\\ 0\\.025276665191312962\ \(0\)\
\-\ presents\\:\\ 0\\.024859618976121177\ \(0\)\
\-\ treatment\\:\\ 0\\.024616808613319854\ \(0\)\
\-\ seen\\:\\ 0\\.02432942098951341\ \(0\)\
\-\ also\\:\\ 0\\.024307687306128315\ \(0\)\
\-\ within\\:\\ 0\\.02380113379039901\ \(0\)\
\-\ which\\:\\ 0\\.02349834335550646\ \(0\)\
\-\ male\\:\\ 0\\.02300887942656913\ \(0\)\
\-\ disease\\:\\ 0\\.021692443206269243\ \(0\)\
\-\ there\\:\\ 0\\.020562378070588274\ \(0\)\
\-\ an\\:\\ 0\\.019761361348553868\ \(0\)\
\-\ was\\:\\ 0\\.01801017398525377\ \(0\)\
\-\ or\\:\\ 0\\.01797773556821475\ \(0\)\
\-\ right\\:\\ 0\\.017133280443908192\ \(0\)\
\-\ patient\\:\\ 0\\.01680814650719407\ \(0\)\
\-\ year\\:\\ 0\\.015926035457916377\ \(0\)\
\-\ old\\:\\ 0\\.015294506973585621\ \(0\)\
